fda semaglutide shortage resolved february 21 2025 Announces GLP-1 Shortage = Over -
Description
GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized weight loss and diabetes care
There are currently no randomized clinical trials specifically focused on microdosing
the trend has been interventionalists performing fewer PCIs prior to TAVR given the benefit is not clear if angina is not a prominent symptom
Arriving prepared with questions helps patients make informed decisions
If weight loss progress has stalled on semaglutide, tirzepatide might provide better appetite control and metabolic improvements
